Abstract:Allogeneic haematopoietic stem cell transplantation (HSCT) leads to the establishment of graft-versus-leukaemia (GVL) immunity, but in many cases also results in the development of graft-versus-host disease (GVHD). This study aimed to determine if P2X7 antagonism using Brilliant Blue G (BBG) could improve the beneficial effects of post-transplant cyclophosphamide (PTCy) in a humanised mouse model of GVHD, without comprising GVL immunity. NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice were injected with human peripheral blood mononuclear cells (PBMCs) (Day 0), then with cyclophosphamide (33 mg/kg) on Days 3 and 4, and with BBG (50 mg/kg) (or saline) on Days 0–10. PTCy with BBG reduced clinical GVHD development like that of PTCy alone. However, histological analysis revealed that the combined treatment reduced liver GVHD to a greater extent than PTCy alone. Flow cytometric analyses revealed that this reduction in liver GVHD by PTCy with BBG corresponded to an increase in human splenic CD39+ Tregs and a decrease in human serum interferon-γ concentrations. In additional experiments, humanised NSG mice, following combined treatment, were injected with human THP-1 acute myeloid leukaemia cells on Day 14. Flow cytometric analyses of liver CD33+ THP-1 cells showed that PTCy with BBG did not mitigate GVL immunity. In summary, PTCy combined with BBG can reduce GVHD without compromising GVL immunity. Future studies investigating P2X7 antagonism in combination with PTCy may lead to the development of novel treatments that more effectively reduce GVHD in allogeneic HSCT patients without promoting leukaemia relapse.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to use post - transplantation cyclophosphamide (PTCy) in combination with Brilliant Blue G (BBG) in allogeneic hematopoietic stem cell transplantation (alloHSCT) to reduce graft - versus - host disease (GVHD) without compromising the effect of graft - versus - leukemia immunity (GVL). Specifically, the study aims to evaluate whether the P2X7 receptor antagonist BBG can improve the beneficial effects of PTCy in a humanized mouse model without affecting GVL immunity. ### Background - **Allogeneic hematopoietic stem cell transplantation (alloHSCT)**: This is a therapy used to treat blood cancers (such as acute myeloid leukemia) by establishing graft - versus - leukemia (GVL) immunity to eliminate the host's malignant cells. - **Graft - versus - host disease (GVHD)**: A major side effect of alloHSCT, caused by the immune attack of donor T cells on host tissues, resulting in damage to organs such as the liver, lungs, intestines, and skin. - **Post - transplantation cyclophosphamide (PTCy)**: A commonly used drug for preventing GVHD, but its effect is limited, and approximately 30% of patients still develop GVHD. - **P2X7 receptor**: A trimeric ligand - gated ion channel expressed on immune cells. Once activated, it promotes inflammation and immune responses and may be involved in the development of GVHD. ### Research Objectives - **Evaluate the effect of combined treatment of PTCy and BBG**: To study whether the combined use of PTCy and BBG can more effectively reduce GVHD without compromising GVL immunity. - **Mechanism exploration**: To explore the potential mechanisms of combined treatment by analyzing changes in immune cells and cytokine levels. ### Main Findings - **Clinical GVHD**: The combined treatment of PTCy and BBG did not significantly reduce the occurrence of clinical GVHD, but the survival rate was improved. - **Liver GVHD**: The combined treatment significantly reduced GVHD in the liver. - **Changes in immune cells**: The combined treatment increased the proportion of CD39+ regulatory T cells in the spleen and decreased the concentration of interferon - γ (IFN - γ) in the serum. - **GVL immunity**: The combined treatment did not affect GVL immunity and was able to effectively control the growth of acute myeloid leukemia (AML) cells. ### Conclusion The combined treatment of PTCy and BBG can reduce GVHD, especially GVHD in the liver, without compromising GVL immunity. This finding provides new ideas for the development of more effective GVHD prevention strategies. Future research will further explore the clinical application potential of the combination of P2X7 antagonists and PTCy.

Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice

Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice

The impact of P2X7 receptor antagonist, brilliant blue G on graft-versus-host disease in mice after allogeneic hematopoietic stem cell transplantation

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐versus‐host disease development in humanized mice treated with post‐transplant cyclophosphamide

Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors

[Effect of BBG on Acute Graft-Versus-Host Disease in Mice after Allogeneic Hematopoietic Stem Cell Transplantation]

Low-dose Post-Transplant Cyclophosphamide Can Mitigate GVHD and Enhance the G-CSF/ATG Induced GVHD Protective Activity and Improve Haploidentical Transplant Outcomes.

Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial

Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG As GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients with Lymphoid Malignancies: A Single Arm Phase II Study

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia

Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation

Low-dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin As an Effective Strategy for GVHD Prevention in Haploidentical Patients.

Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression

Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study

Low-dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide As Graft-Versus-host Disease Prophylaxis in Haploidentical Peripheral Blood Stem Cell Transplantation Combined with Unrelated Cord Blood for Patients with Hematologic Malignancies: a Prospective, Phase II Study

PTCy versus CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin Lymphoma: a study of the LWP of the EBMT

Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation